Catalan Biotechs Boosted By International Backers
Executive Summary
The number of foreign investors participating in Catalan biotech companies has gone from 0 to 50, and over the past five years alone, the figure has increased tenfold, according to the latest Biocat report.
You may also be interested in...
Qiagen Buys STAT-Dx To Launch Next-Gen Syndromic Testing System
Qiagen has agreed to acquire STAT-Dx, a start-up that developed a multiplex diagnostic for common syndromes, for about $147m in upfront cash, and up to $44m in regulatory and commercial milestones.
Catalonia In Danger Of Failing Pharma Stability Test
Other companies in the sector could follow Spanish flagship biotech Oryzon and move their headquarters to Madrid, leaving a big hole in the coffers of the Catalan government.
Spain's Oryzon Moves To Madrid From Barcelona As Catalan Crisis Deepens
As tensions continue to rise in Catalonia in the aftermath of the illegal independence referendum, one of Spain's most high-profile biotechs has decided to move its headquarters to Madrid, leaving observers to wonder if other companies, including multinationals, will follow.